Scholarlink

<p>This study evaluates the potential of [<sup>99m</sup>Tc]Tc-DTPA-Nimotuzumab (labeled cpd) as a radiolabeled agent for targeting Epidermal Growth Factor Receptor (EGFR) overexpression in head and neck squamous cell carcinoma (HNSCC). Nimotuzumab was conjugated with a bifunctional chelator and labeled with <sup>99m</sup>Tc, achieving over 98% radiochemical purity with 24&#xa0;h stability. In vitro studies showed progressive internalization in HNSCC cells, with optimal uptake at 20&#xa0;µg. Biodistribution in mice confirmed selective tumor accumulation with minimal off target effects, supporting its promise as a targeted imaging agent for EGFR expression in HNSCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis of [99mTc]Tc-DTPA-Nimotuzumab: EGFR overexpression in head and neck squamous cell carcinoma

  • 期刊论文

  • 发表日期：

    2025年9月24日

查看全文
  • Muhammad Shehzad Saleem,
  • Syed Qaiser Shah

摘要

This study evaluates the potential of [99mTc]Tc-DTPA-Nimotuzumab (labeled cpd) as a radiolabeled agent for targeting Epidermal Growth Factor Receptor (EGFR) overexpression in head and neck squamous cell carcinoma (HNSCC). Nimotuzumab was conjugated with a bifunctional chelator and labeled with 99mTc, achieving over 98% radiochemical purity with 24 h stability. In vitro studies showed progressive internalization in HNSCC cells, with optimal uptake at 20 µg. Biodistribution in mice confirmed selective tumor accumulation with minimal off target effects, supporting its promise as a targeted imaging agent for EGFR expression in HNSCC.